Key Takeaways from CDDF Live Webinar Series – “AI and Big Data AI in Drug Development: Use of AI in Clinical Trials” (12 May 2026)
The CDDF is pleased to share the key takeaways from our live webinar series – “AI and Big Data AI in Drug Development: Use of AI in clinical trials” held on 12 May 2026. This webinar included a lecture by Dr. James Gulley (NIH) followed by a 30-minute Q&A...
![[ACT EU Workplan for 2026-2027 – Version 4, May 2026]](https://cddf.org/wp-content/uploads/2026/05/Capture-400x250.jpg)
[ACT EU Workplan for 2026-2027 – Version 4, May 2026]
The ACT EU workplan for 2026 – 2027 has been adopted by the ACT EU Steering Group and is now published. The workplan reflects the revised ACT EU objectives and takes into account recent legislative and policy developments including the proposed Biotech Act, the...
Executive Summary: CDDF & AAADV Workshop – Challenges in the Landscape of a Global Development Strategy Including Patient Access (30-31 March 2026, BE)
The Cancer Drug Development Forum (CDDF) is delighted to announce that the executive summary of the CDDF & AAADV joint workshop on “Challenges in the Landscape of a Global Development Strategy Including Patient Access” has been published today. This...
![[News from ACT EU] – Clinical Trials Information System (CTIS): training and support](https://cddf.org/wp-content/uploads/2026/04/Copy-of-PUBLICATION-Annual-Repport-2024-Is-available-4-400x250.jpg)
[News from ACT EU] – Clinical Trials Information System (CTIS): training and support
Check out the publication of a new EMA document of frequently asked questions (FAQ) for sponsors on the Clinical Trials Information System (CTIS):...
Interim Report: ACT EU pilots on consolidated scientific and regulatory advice
The interim results from the ACT EU pilots on consolidated scientific and regulatory advice have been published and available to stakeholders. These pilots were launched to offer harmonised advice on how to improve the quality of applications for clinical trials and...
![[CDDF NEW WHITE PAPER: Challenges and Potential Solutions to Advance Global Cancer Drug Development]](https://cddf.org/wp-content/uploads/2026/03/202603_Challenges-and-Potential-Solutions-to-Advance-Global-Cancer-Drug-Development-400x250.jpg)
[CDDF NEW WHITE PAPER: Challenges and Potential Solutions to Advance Global Cancer Drug Development]
We are delighted to announce that CDDF’s new white paper, Challenges and Potential Solutions to Advance Global Cancer Drug Development, has been published in the journal Therapeutic Innovation & Regulatory Science. This paper reflects on multi-stakeholder...
CDDF Diversity Initiative: In-Person Meeting in Brussels Today
Following several work package meetings over the past 10 months, the final project meeting for the Diversity Initiative is in full swing in Brussels. Our multi-stakeholder working group members and experts have gathered to advance their work on developing and...
![[EMA News] Public Consultation: Concept Paper on Guideline Revision on Good Pharmacogenomic Practice](https://cddf.org/wp-content/uploads/2026/03/EMA-News-400x250.jpg)
[EMA News] Public Consultation: Concept Paper on Guideline Revision on Good Pharmacogenomic Practice
🔔📢The European Medicines Agency has published for public consultation: a Concept paper on the guideline revision on good pharmacogenomic practice. Since its initial publication in 2018, the guideline on good pharmacogenomic practice has played a crucial role in...
Multi-stakeholder Interview: Get an Inside Look at the CDDF Annual Conference 2026
We are excited to share interview clips featuring a diverse group of stakeholders at this year’s CDDF annual conference. Held in Ghent on 9-11 February, the meeting highlighted multi-stakeholder collaboration as the cornerstone of our shared mission to improve cancer...